Internal Medicine, Endocrinology, Diabetes, & Metabolism · Mesa, AZ
NPI
1275724452
Since 2007
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
10238 E Hampton Ave
Mesa, AZ, 85209
Phone (480) 257-2669
Groups this clinician bills Medicare through
Medicare paid, 2024
$143K
10,469 services
Medicare patients, 2024
591
Average age 73
Drug cost, 2024
$3.3M
4,671 prescriptions
Company payments, 2025
$18K
From 34 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Vidhyalakshmi Kannan was code 99214 (office e&m - established), 922 times for 511 patients. In total Vidhyalakshmi Kannan billed 10,469 services in 11 codes, and Medicare paid $143K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-02-06.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 922 | 511 | $90.43 | $83K |
| 95251 Test - Miscellaneous | Office | 355 | 174 | $24.93 | $8,849 |
| 99205 Office E&M - New | Office | 83 | 83 | $146.74 | $12K |
| 99215 Office E&M - Established | Office | 52 | 47 | $123.40 | $6,417 |
| 99213 Office E&M - Established | Office | 47 | 46 | $64.01 | $3,008 |
| 99204 Office E&M - New | Office | 25 | 25 | $113.17 | $2,829 |
By year: 2022 $86K for 1,082 services; 2023 $106K for 1,245 services; 2024 $143K for 10,469 services.
Medicare prescription drug claims, 2024
In 2024, the drug Vidhyalakshmi Kannan prescribed most often to Medicare patients was Levothyroxine Sodium, with 820 prescriptions and refills. In total Vidhyalakshmi Kannan wrote 4,671 Medicare prescriptions that cost $3.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 820 | 2,296 | 253 | $8,520 |
| Metformin Hcl Generic | 295 | 847 | 100 | $2,468 |
| Jardiance Empagliflozin | 165 | 422 | 58 | $239K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 160 | 398 | 69 | $28K |
| Trulicity Dulaglutide | 147 | 264 | 52 | $257K |
| Ozempic Semaglutide | 146 | 308 | 59 | $276K |
| Atorvastatin Calcium Generic | 144 | 429 | 51 | $1,568 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 121 | 318 | 55 | $18K |
| Liothyronine Sodium Generic | 108 | 311 | 33 | $4,587 |
| Novolog Flexpen Insulin Aspart | 105 | 263 | 45 | $49K |
| Synthroid Levothyroxine Sodium | 97 | 272 | 41 | $9,856 |
| Metformin Hcl Er Metformin Hcl | 89 | 265 | 37 | $893 |
| Humalog Kwikpen U-100 Insulin Lispro | 84 | 206 | 38 | $30K |
| Mounjaro Tirzepatide | 82 | 131 | 24 | $136K |
| Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 | 73 | 138 | 16 | $86K |
Brand drugs: 2,327 claims; generic drugs: 1,919 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Vidhyalakshmi Kannan $18K ($18K in general payments such as food, travel and fees) from 34 companies. The largest payer was Corcept Therapeutics with $13K.
| Company | Payments | Amount |
|---|---|---|
| Corcept Therapeutics CORT | 24 | $13K |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $1,202 |
| Medtronic, Inc. MDT | 21 | $1,065 |
| Beta Bionics, Inc. BBNX | 23 | $383 |
| Xeris Pharmaceuticals, Inc. | 18 | $307 |
| Sanofi-Aventis U.S. LLC SNY | 7 | $268 |
| Ascendis Pharma Endocrinology Inc ASND | 7 | $182 |
| Insulet Corporation PODD | 11 | $171 |
| Recordati_rare_diseases_inc. | 9 | $159 |
| Lilly USA, LLC LLY | 5 | $103 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.